CH-1504
Code | Size | Price |
---|
TAR-T27002-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27002-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27002-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
CH-1504, dihydrofolate reductase (DHFR) inhibitor, is used potentially for the treatment of rheumatoid arthritis.
CAS:
238074-89-0
Formula:
C23H23N5O5
Molecular Weight:
449.467
Purity:
0.98
SMILES:
Nc1nc(N)c2cc(CCc3ccc(cc3)C(=O)NC(CC(=C)C(O)=O)C(O)=O)ccc2n1
References
1. Keystone EC, Shirinsky VS, Simon LS, Pedder S, Hewitt LA; CH-1504 Study Group.. Efficacy and safety of CH-1504, a metabolically stable antifolate, in patients with active rheumatoid arthritis: results of a phase II multicenter randomized study. J Rheumatol. 2011 Sep;38(9):1875-83. doi: 10.3899/jrheum.101038. PubMed PMID: 21724705.
2. Bajpai M. CH-1504, a metabolically inert antifolate for the potential treatment of rheumatoid arthritis. IDrugs. 2010 Aug;13(8):559-67. Review. PubMed PMID: 20721827.
3. McGuire JJ, Haile WH. Metabolism-blocked antifolates as potential anti-rheumatoid arthritis agents: 4-amino-4-deoxy-5,8,10-trideazapteroyl-d,l-4'-methyleneglutamic acid (CH-1504) and its analogs. Biochem Pharmacol. 2009 Apr 1;77(7):1161-72. doi: 10.1016/j.bcp.2008.12.020. PubMed PMID: 19174154.
4. Mant T, Jurcevic S, Szakacs C, Adams L, Boland J, Hewitt LA. Two single-center, double-blind, randomized, placebo-controlled, phase I studies to investigate the tolerability and pharmacokinetics of CH-1504, an antifolate, in healthy male subjects. Clin Ther. 2008 Jan;30(1):131-42. doi: 10.1016/j.clinthera.2008.01.017. PubMed PMID: 18343249.